Effects of dietary flaxseed lignan extract on symptoms of benign prostatic hyperplasia.

A flaxseed lignan extract containing 33% secoisolariciresinol diglucoside (SDG) was evaluated for its ability to alleviate lower urinary tract symptoms (LUTS) in 87 subjects with benign prostatic hyperplasia (BPH). A randomized, double-blind, placebo-controlled clinical trial with repeated measurements was conducted over a 4-month period using treatment dosages of 0 (placebo), 300, or 600 mg/day SDG. After 4 months of treatment, 78 of the 87 subjects completed the study. For the 0, 300, and 600 mg/day SDG groups, respectively, the International Prostate Symptom Score (IPSS) decreased -3.67 +/- 1.56, -7.33 +/- 1.18, and -6.88 +/- 1.43 (mean +/- SE, P = .100, < .001, and < .001 compared to baseline), the Quality of Life score (QOL score) improved by -0.71 +/- 0.23, -1.48 +/- 0.24, and -1.75 +/- 0.25 (mean +/- SE, P = .163 and .012 compared to placebo and P = .103, < .001, and < .001 compared to baseline), and the number of subjects whose LUTS grade changed from "moderate/severe" to "mild" increased by three, six, and 10 (P = .188, .032, and .012 compared to baseline). Maximum urinary flows insignificantly increased 0.43 +/- 1.57, 1.86 +/- 1.08, and 2.7 +/- 1.93 mL/second (mean +/- SE, no statistical significance reached), and postvoiding urine volume decreased insignificantly by -29.4 +/- 20.46, -19.2 +/- 16.91, and -55.62 +/- 36.45 mL (mean +/- SE, no statistical significance reached). Plasma concentrations of secoisolariciresinol (SECO), enterodiol (ED), and enterolactone (EL) were significantly raised after the supplementation. The observed decreases in IPSS and QOL score were correlated with the concentrations of plasma total lignans, SECO, ED, and EL. In conclusion, dietary flaxseed lignan extract appreciably improves LUTS in BPH subjects, and the therapeutic efficacy appeared comparable to that of commonly used intervention agents of alpha1A-adrenoceptor blockers and 5alpha-reductase inhibitors.

[1]  C. Saussine,et al.  Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice , 2006, BJU international.

[2]  I. Romics,et al.  A novel approach to the treatment of benign prostatic hyperplasia , 2006, BJU international.

[3]  T. Deguchi,et al.  Comparison of two α1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study , 2006, BJU international.

[4]  T. Kitamura,et al.  Clinical efficacy of an α1A/D‐adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia , 2006 .

[5]  P. van’t Veer,et al.  The relative bioavailability of enterolignans in humans is enhanced by milling and crushing of flaxseed. , 2005, The Journal of nutrition.

[6]  H. Origasa,et al.  Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial , 2005, BJU international.

[7]  A. Zlotta,et al.  Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride. , 2005, European urology.

[8]  Jørgen Nordling,et al.  Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia , 2005, BJU international.

[9]  S. Hong,et al.  Doxazosin for benign prostatic hyperplasia: An open‐label, baseline‐controlled study in Korean general practice , 2005, International journal of urology : official journal of the Japanese Urological Association.

[10]  C. Roehrborn,et al.  Efficacy and Safety of Long-Term Treatment with the Dual 5α-Reductase Inhibitor Dutasteride in Men with Symptomatic Benign Prostatic Hyperplasia , 2004 .

[11]  D. Tindall,et al.  Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. , 2004, The Journal of urology.

[12]  R. Sakakibara,et al.  Single‐blind, randomized controlled study of the clinical and urodynamic effects of an α‐blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia , 2004, International journal of urology : official journal of the Japanese Urological Association.

[13]  P. Boyle,et al.  Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis. , 2004, European urology.

[14]  N. Kyprianou,et al.  Apoptotic impact of α1‐blockers on prostate cancer growth: A myth or an inviting reality? , 2004, The Prostate.

[15]  R. Kirby,et al.  Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis , 2004, International journal of clinical practice.

[16]  C. Roehrborn,et al.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. , 2003, The New England journal of medicine.

[17]  A. Erol,et al.  Short‐term subjective efficacy of doxazosin in predicting probability of prostatectomy in the management of benign prostatic hyperplasia in patients with severe symptoms , 2003, International journal of urology : official journal of the Japanese Urological Association.

[18]  Y. Ogawa,et al.  Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia , 2003, International journal of urology : official journal of the Japanese Urological Association.

[19]  I. Ikemoto,et al.  Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: A comparative, randomized, two‐drug crossover study , 2003, International journal of urology : official journal of the Japanese Urological Association.

[20]  P. Åman,et al.  High-performance liquid chromatographic analysis of secoisolariciresinol diglucoside and hydroxycinnamic acid glucosides in flaxseed by alkaline extraction. , 2003, Journal of chromatography. A.

[21]  J. Eden,et al.  Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial , 2003, BJU international.

[22]  R. Kirby.  A randomized, double‐blind crossover study of tamsulosin and controlled‐release doxazosin in patients with benign prostatic hyperplasia , 2003, BJU international.

[23]  H. Adlercreutz.  Phyto-oestrogens and cancer. , 2002, The Lancet. Oncology.

[24]  P. Boyle,et al.  [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study]. , 2002, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[25]  W. Demark-Wahnefried,et al.  Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. , 2001, Urology.

[26]  S. Kaplan,et al.  Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. , 2001, Urology.

[27]  R. Kirby,et al.  A combined analysis of double‐blind trials of the efficacy and tolerability of doxazosin‐gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia , 2001, BJU international.

[28]  P. Narayan,et al.  A comparison of two phase III multicenter, placebo-controlled studies of tamsulosin in BPH , 2000, Advances in therapy.

[29]  J. Sökeland.  Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome , 2000, BJU international.

[30]  M. Guil,et al.  The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia , 2000, BJU international.

[31]  T. Tsujii.  Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: A short‐term open, randomized multicenter study , 2000, International journal of urology : official journal of the Japanese Urological Association.

[32]  T. Senge,et al.  Treatment of symptomatic benign prostatic hyperplasia with β‐sitosterol: an 18‐month follow‐up , 2000, BJU international.

[33]  A. Partin,et al.  Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. , 2000, The Journal of urology.

[34]  S. Kamidono,et al.  A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients , 2000, BJU international.

[35]  H. Mori,et al.  Prediction of alpha-blocker response in men with benign prostatic hyperplasia by magnetic resonance imaging. , 1999, Urology.

[36]  R. Guthrie,et al.  A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT). , 1999, Clinical therapeutics.

[37]  C. Chatelain,et al.  Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. , 1999, Urology.

[38]  J. Trachtenberg,et al.  Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group. , 1999, Urology.

[39]  P. Nesbitt,et al.  Human metabolism of mammalian lignan precursors in raw and processed flaxseed. , 1999, The American journal of clinical nutrition.

[40]  P. Boyle,et al.  Double‐blind, placebo‐controlled trial to assess the efficacy and tolerability of mepartricin in the treatment of BPH , 1998, The Prostate.

[41]  H. Lepor.  Long-Term Evaluation of Tamsulosin in Benign Prostatic Hyperplasia: Placebo-Controlled, Double-Blind Extension of Phase III Trial , 1998 .

[42]  G. Chodak,et al.  Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. , 1998, Urology.

[43]  H. Lepor.  Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. , 1998, Urology.

[44]  M. Marberger.  Long-Term Effects of Finasteride in Patients with Benign Prostatic Hyperplasia: A Double-Blind, Placebo-Controlled, Multicenter Study , 1998 .

[45]  J. Nickel.  Placebo therapy of benign prostatic hyperplasia: a 25-month study. Canadian PROSPECT Study Group. , 1998, British journal of urology.

[46]  W. Witjes,et al.  Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. , 1997, British journal of urology.

[47]  E. Lee,et al.  Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. , 1997, British journal of urology.

[48]  K. Kawabe,et al.  Transition zone ratio and prostate-specific antigen density as predictors of the response of benign prostatic hypertrophy to alpha blocker and anti-androgen therapy. , 1997, British journal of urology.

[49]  E. Ghisalberti.  Cardiovascular activity of naturally occurring lignans. , 1997, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[50]  K. Griffiths,et al.  Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. , 1995, The Journal of endocrinology.

[51]  K. Griffiths,et al.  Determination of lignans and isoflavonoids in human female plasma following dietary supplementation. , 1994, The Journal of endocrinology.

[52]  C. Bosman,et al.  Combination Therapy with Rofecoxib and Finasteride in the Treatment of Men with Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic Hyperplasia (BPH) , 2005 .

[53]  M. Safarinejad.  Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. , 2005, Journal of herbal pharmacotherapy.

[54]  H. Preuss,et al.  Randomized trial of a combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH) , 2004, International Urology and Nephrology.

[55]  H. Adlercreutz,et al.  Phytoestrogens, cancer and coronary heart disease , 2004, BioFactors.

[56]  L. Bloedon,et al.  Flaxseed and cardiovascular risk. , 2004, Nutrition reviews.

[57]  P. Wiesenfeld,et al.  Effect of flaxseed consumption on male and female reproductive function and fetal development. , 2003 .

[58]  P. Boyle,et al.  Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. , 2003, Urology.

[59]  N. Kyprianou,et al.  Induction of prostate apoptosis by α1-adrenoceptor antagonists: mechanistic significance of the quinazoline component , 2002, Prostate Cancer and Prostatic Diseases.

[60]  P. V. Van Cangh,et al.  Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. , 2002, European urology.